128 related articles for article (PubMed ID: 38267332)
21. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia.
Gidding HF; McCallum L; Fathima P; Moore HC; Snelling TL; Blyth CC; Jayasinghe S; Giele C; de Klerk N; Andrews RM; McIntyre PB;
Vaccine; 2018 May; 36(19):2650-2656. PubMed ID: 29627233
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of pneumococcal nasopharyngeal colonization and serotypes circulating in Cameroonian children after the 13-valent pneumococcal conjugate vaccine introduction.
Njuma Libwea J; Gröndahl-Yli-Hannuksela K; Kobela M; Toropainen M; Nyholm O; Ndombo PK; Koulla-Shiro S; Nohynek H; Nuorti JP; Vuopio J; Palmu AA
Int J Infect Dis; 2020 Sep; 98():113-120. PubMed ID: 32562849
[TBL] [Abstract][Full Text] [Related]
23. Effect of the different 13-valent pneumococcal conjugate vaccination uptakes on the invasive pneumococcal disease in children: Analysis of a hospital-based and population-based surveillance study in Madrid, Spain, 2007-2015.
Picazo J; Ruiz-Contreras J; Casado-Flores J; Negreira S; Baquero F; Hernández-Sampelayo T; Otheo E; Méndez C;
PLoS One; 2017; 12(2):e0172222. PubMed ID: 28207888
[TBL] [Abstract][Full Text] [Related]
24. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).
American Academy of Pediatrics Committee on Infectious Diseases
Pediatrics; 2010 Jul; 126(1):186-90. PubMed ID: 20498180
[TBL] [Abstract][Full Text] [Related]
25. Analysis of 13-valent pneumococcal polysaccharide conjugate vaccine among children born in Hangzhou from 2017 to 2021.
Che X; Chen Q; Liu Y; Gu L; Lu Z; Gu W; Wang J; Jiang W; Du J; Zhang X; Xu Y; Zhang X; Wang J; Xie Q; Yang Y
Front Public Health; 2023; 11():1184059. PubMed ID: 37325318
[TBL] [Abstract][Full Text] [Related]
26. Serotype distribution of Streptococcus pneumoniae isolated from children hospitalized in Beijing children's hospital (2013-2019).
Wang Q; Shi W; Li Y; Gao W; Yuan L; Dong F; Yao K
Vaccine; 2020 Nov; 38(49):7858-7864. PubMed ID: 33164807
[TBL] [Abstract][Full Text] [Related]
27. Streptococcus pneumoniae colonization after introduction of 13-valent pneumococcal conjugate vaccine for US adults 65 years of age and older, 2015-2016.
Milucky J; Carvalho MG; Rouphael N; Bennett NM; Talbot HK; Harrison LH; Farley MM; Walston J; Pimenta F; Lessa FC;
Vaccine; 2019 Feb; 37(8):1094-1100. PubMed ID: 30685247
[TBL] [Abstract][Full Text] [Related]
28. Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study.
Ricketson LJ; Bettinger JA; Sadarangani M; Halperin SA; Kellner JD;
Vaccine; 2022 Apr; 40(19):2733-2740. PubMed ID: 35351324
[TBL] [Abstract][Full Text] [Related]
29. Economic and clinical evaluation of a catch-up dose of 13-valent pneumococcal conjugate vaccine in children already immunized with three doses of the 7-valent vaccine in Italy.
Boccalini S; Azzari C; Resti M; Valleriani C; Cortimiglia M; Tiscione E; Bechini A; Bonanni P
Vaccine; 2011 Nov; 29(51):9521-8. PubMed ID: 22008820
[TBL] [Abstract][Full Text] [Related]
30. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China.
Shen K; Wasserman M; Liu D; Yang YH; Yang J; Guzauskas GF; Wang BCM; Hilton B; Farkouh R
PLoS One; 2018; 13(7):e0201245. PubMed ID: 30044865
[TBL] [Abstract][Full Text] [Related]
31. Pneumococcal nasopharyngeal carriage in children <5 years of age visiting the pediatric emergency room in relation to PCV7 and PCV13 introduction in southern Israel.
Ben-Shimol S; Givon-Lavi N; Greenberg D; Dagan R
Hum Vaccin Immunother; 2016; 12(2):268-76. PubMed ID: 26430921
[TBL] [Abstract][Full Text] [Related]
32. Towards the 13-valent pneumococcal conjugate universal vaccination: effectiveness in the transition era between PCV7 and PCV13 in Italy, 2010-2013.
Martinelli D; Pedalino B; Cappelli MG; Caputi G; Sallustio A; Fortunato F; Tafuri S; Cozza V; Germinario C; Chironna M; Prato R;
Hum Vaccin Immunother; 2014; 10(1):33-9. PubMed ID: 24096297
[TBL] [Abstract][Full Text] [Related]
33. Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States.
McLaughlin JM; Swerdlow DL; Khan F; Will O; Curry A; Snow V; Isturiz RE; Jodar L
Hum Vaccin Immunother; 2019; 15(4):841-849. PubMed ID: 30676236
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
[TBL] [Abstract][Full Text] [Related]
35. A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age.
Chu K; Hu Y; Pan H; Wu J; Zhu D; Young MM; Luo L; Yi Z; Giardina PC; Gruber WC; Scott DA; Watson W
Hum Vaccin Immunother; 2023 Aug; 19(2):2235926. PubMed ID: 37549923
[No Abstract] [Full Text] [Related]
36. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
[TBL] [Abstract][Full Text] [Related]
37. Evolving role of 13-valent pneumococcal conjugate vaccine in clinical practice.
Azzari C; Martinón-Torres F; Schmitt HJ; Dagan R
Pediatr Infect Dis J; 2014 Aug; 33(8):858-64. PubMed ID: 24618937
[TBL] [Abstract][Full Text] [Related]
38. Pneumococcal carriage in children in Ulaanbaatar, Mongolia before and one year after the introduction of the 13-valent pneumococcal conjugate vaccine.
von Mollendorf C; Dunne EM; La Vincente S; Ulziibayar M; Suuri B; Luvsantseren D; Narangerel D; Ortika BD; Pell CL; Nation ML; Alamrousi A; Hinds J; Demberelsuren S; Nguyen C; Mungun T; Mulholland EK; Satzke C
Vaccine; 2019 Jul; 37(30):4068-4075. PubMed ID: 31174939
[TBL] [Abstract][Full Text] [Related]
39. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
[TBL] [Abstract][Full Text] [Related]
40. Understanding vaccine hesitancy with PCV13 in children: Results of a survey in Shanghai, China.
Ni YH; Xu ZH; Wang J
PLoS One; 2023; 18(4):e0284810. PubMed ID: 37104479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
